My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bayer

< Previous 1 2 3 4 5 6 7 8 9 Next >
Bayer Launches Calantic™ Digital Solutions to help Address Radiology Industry Challenges
From Bayer
Via Business Wire
Midol® Encourages Menstruators to Find Comfort in Speaking Up and Acknowledging ‘The Real Reason’ Behind Changing Plans When Period Symptoms Strike
From Bayer
Via Business Wire
Bayer and Luke Bryan Continue Partnership to Celebrate America’s Farmers and Fight Hunger with #HeresToTheFarmer Campaign
From Bayer
Via Business Wire
Bayer’s Vividion Emerging as Significant Player in San Diego Biotech Hub
From Bayer
Via Business Wire
Bayer Appoints Two New Members to U.S. Country Leadership Team
From Bayer
Via Business Wire
Bayer to Present Key Data Across Oncology Portfolio Showcasing Significant Advances in Cancer Care at 2022 ASCO Annual Meeting
From Bayer
Via Business Wire
U.S. FDA Accepts Supplemental New Drug Application (sNDA) and Grants Priority Review for NUBEQA® (darolutamide) in Combination with Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
From Bayer
Via Business Wire
Claritin® Teams Up with Nate Berkus and Jeremiah Brent to Inspire Families to Spend More Time Outside and Embrace their Outdoor Space
From Bayer
Via Business Wire
Bayer to Create Ag Biologicals Powerhouse Partnership with Ginkgo Bioworks, Advancing Joyn Bio Technology Platforms
From Bayer
Via Business Wire
Bayer Presents New Subgroup Analyses for KERENDIA® (finerenone) for Chronic Kidney Disease Associated With Type 2 Diabetes With or Without History of Atherosclerotic Cardiovascular Disease
From Bayer
Via Business Wire
Bayer Set to Drive Breakthrough Innovations in the Life Sciences
From Bayer
Via Business Wire
Bayer to Highlight New Cardiovascular and Renal Data at ACC.22, Including Late-Breaking Presentations for KERENDIA® (finerenone) as Well as Oral Factor XIa Inhibitor (asundexian) Program
From Bayer
Via Business Wire
Stem and Root and Nutrileads Announce Launch of Daily Immunity for Optimized Immune Function Powered by BeniCaros for Ground Breaking Immunity Support
From Bayer
Via Business Wire
Positive Results from Phase III Investigational Trial Shows NUBEQA® (darolutamide) Plus Androgen Deprivation Therapy (ADT) and Docetaxel Significantly Increases Overall Survival (OS) in Patients with mHSPC
From Bayer
Via Business Wire
Bayer Highlights Advancements of Agriculture Industry’s Most Prolific R&D Pipeline
From Bayer
Via Business Wire
Bayer Receives FDA Fast Track Designation for asundexian Stroke Program
From Bayer
Via Business Wire
Bayer Earns Top Score in 2022 Corporate Equality Index for Fifth Consecutive Year
From Bayer
Via Business Wire
Bayer to Launch Project Carbonview, an Industry-First Digital Carbon Footprint Measurement Solution for Agriculture
From Bayer
Via Business Wire
Phase III Investigational Trial of NUBEQA® (darolutamide) in Combination with Docetaxel and Androgen Deprivation Therapy (ADT) Meets Primary Endpoint of Significantly Increasing Overall Survival (OS) in Patients with mHSPC
From Bayer
Via Business Wire
Bayer Invests €100 million in Sustainable Health Products to Advance Company’s 2030 Sustainability Commitments
From Bayer
Via Business Wire
Bayer Wins U.S. Chamber of Commerce Foundation’s Annual Citizens Award
From Bayer
Via Business Wire
Bayer Presented New Analyses Investigating KERENDIA® (finerenone) on Cardiovascular Outcomes in Patients With Chronic Kidney Disease Associated With Type 2 Diabetes
From Bayer
Via Business Wire
Bayer, Microsoft Enter Into Strategic Partnership to Optimize and Advance Digital Capabilities for Food, Feed, Fuel, Fiber Value Chain
From Bayer
Via Business Wire
Bayer Focuses on Farmers and Drives Innovation into 2022
From Bayer
Via Business Wire
Effective January 1, 2022: Rodrigo Santos Named Member of the Board of Management, Bayer AG, and President of the Crop Science Division
From Bayer
Via Business Wire
Bayer Presents New Subgroup Analysis of Prespecified Pooled Analysis of Phase III Studies for KERENDIA® (finerenone) for Chronic Kidney Disease Associated With Type 2 Diabetes With or Without SGLT2i Use at Baseline
From Bayer
Via Business Wire
Bayer Consumer Health Media Team Named AdExchanger Winner for Best In-House Media Operations
From Bayer
Via Business Wire
Bayer and CHS Collaborate to Bring Carbon Program Access to More Farmers
From Bayer
Via Business Wire
Bayer to present new analyses adding to the depth of knowledge on the cardiovascular and renal outcomes of KERENDIA® (finerenone)
From Bayer
Via Business Wire
During Breast Cancer Awareness Month, Bayer Shines a Light on the Impact of Breast Density on Breast Cancer Risk
From Bayer
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.